EGFR has been previously shown to induce metabolic reprograming through PI3K/AKT pathway activation [74] or c-Myc upregulation [75]; however, specific dependencies in NSCLC remain unclear. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.